
A new 21-valent pneumococcal conjugate vaccine, Capvaxive, has been approved by the FDA to protect adults against invasive pneumococcal disease and pneumococcal pneumonia.


coremsg

The new vaccine covers eight serotypes not protected by other vaccines already on the market.

New Pneumococcal Vaccine Approved

new-21-valent-pneumococcal-vaccine-approved-for-adults-to-prevent-invasive-disease-and-pneumonia


New 21-Valent Pneumococcal Vaccine Approved for Adults to Prevent Invasive Disease and Pneumonia
